Specify a stock or a cryptocurrency in the search bar to get a summary
Indaptus Therapeutics Inc
INDPIndaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Address: Three Columbus Circle, New York, NY, United States, 10019
Analytics
WallStreet Target Price
10 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures INDP
Dividend Analytics INDP
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History INDP
Stock Valuation INDP
Financials INDP
Results | 2019 | Dynamics |